Treatment Strategies and Survival Outcomes in Breast Cancer

Edited by
April 2020
264 pages
  • ISBN978-3-03928-758-1 (Hardback)
  • ISBN978-3-03928-759-8 (PDF)

This book is a reprint of the Special Issue Treatment Strategies and Survival Outcomes in Breast Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival.
  • Hardback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
advanced breast cancer; metastatic; chemotherapy; antihormone therapy; HER2 c-erbB2; HER2/neu; trastuzumab; pertuzumab; T-DM1; lapatinib; LKB1; Breast Cancer; Older women; Metformin; Endocrine therapy; breast cancer; breast-conserving therapy; mastectomy; outcome; comparative effectiveness; metastatic breast cancer; liquid biopsy; cell-free DNA; next-generation sequencing; circulating tumor cells; overdiagnosis; mammography screening; invasive breast cancer; zero-inflated Poisson regression model; breast cancer; stage IV; incidence; tumor biology; NCDB; SEER; Src kinase; basal-like breast cancer; cMet; breast cancer; radiotherapy; lymph-node ratio; disease-free survival; physical activity; breast cancer survivors; physical function; social well-being; exercise characteristics; APOBEC3B; gene expression; breast cancer; ductal carcinoma in situ; infiltrating breast cancer; PIK3CA; ERCC1; anthracycline resistance; taxane sensitivity; breast cancer; colorectal cancer; relative survival; older patients; geriatric oncology; cancer treatment; metastatic breast cancer; lactate dehydrogenase; serum biomarker; LDH; monitoring metastatic breast cancer; palbociclib; ribociclib; abemaciclib; fulvestrant; aromatase inhibitors; metastatic breast cancer; contralateral prophylactic mastectomy; contralateral breast cancer; BRCA; CHEK2; PALB2; ATM; mutation carriers; family history; survival; breast cancer; young women; histone deacetylase; HDAC5 inhibitors; LMK-235; breast cancer; cyclin E; older patients; biomarker; tumor biology; prognosis; survival; n/a